Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 595-604

  Eckhardt, S Gail ^a,f   Baker, Sharyn D ^a   Eckardt, John R ^a   Burke, Thomas G ^b   Warner, Deanna L ^b   Kuhn, John G ^c   Rodriguez, Gladys ^a   Fields, Suzanne ^a   Thurman, Allison ^a   Smith, Lon ^a   Rothenberg, Mace L ^c   White, Linda ^a   Wissel, Paul ^e   Kunka, Robert ^e   DePee, Scott ^e   Littlefield, Diane ^e   Burris, Howard A ^d   Von Hoff, Daniel D ^a   Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

^b University of Kentucky   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d BROOKE ARMY MEDICAL CENTER   (United States)

^e GLAXOSMITHKLINE   (United States)

^f University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; GL 147211; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ELIMINATION; FEMALE; HUMAN; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 15644373056     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Besterman, J. M. Topoisomerase I inhibition by the camptothecin analog GI147211C. Ann. N. Y. Acad. Sci., 803: 202-209, 1996.
2. Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T., and Block, J. B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep., 54: 461-470, 1970.
3. Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. H., and Selawry, O. S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep., 56: 515-521, 1972.
4. 1a,b Synthesis and structure activity of novel camptothecin analogs. J. Med. Chem., 36: 2691-2700, 1993.
5. Emerson, D. L., Besterman, J. M., Brown, H. R., Evans, M. G., Leitner, P. P., Luzzio, M. J., Shaffer, J. E., Sternbach, D. D., Uehling, D., and Vuong, A. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res., 55: 603-609, 1995.
6. Glaxo Wellcome Research and Development. Clinical Investigator's Brochure. Research Triangle Park, NC: Glaxo Wellcome Research and Development, 1993.
7. Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., Kaufmann, S. H., and Donehower, R. C. Phase I and pharmacologie study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647-656, 1992.
8. WHO. WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset Publ. No. 48. Geneva: WHO, 1979.
9. Stafford, C. G., and St. Claire, R. L., III. High-performance liquid Chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma. J. Chromatogr. B., 663: 119-126, 1995.
10. D'Argenio, D. Z., and Schumitzky, A. ADAPT II User's Guide. Los Angeles: University of Southern California Biomedical Simulations Resource, 1990.
11. Yamaoka, K., Nakagaawa, T., and Uno, T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6: 165-175, 1978.
12. Gibaldi, M., and Perrier, D. Pharmacokinetics, Ed. 2, pp. 113-144. New York: Marcel Dekker, 1982.
13. Lalonde, R. L. Pharmacodynamics. In: W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, pp. 4-1-4-33. Vancouver, WA: Applied Therapeutics, 1992.
14. Burke, T. G., Mishra, A. K., Wani, M. C., and Wall, M. E. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry, 32: 5352-5364, 1993.
15. Slichenmyer, W. J., Rowinsky, E. K., Donnehower, R. C., and Kaufman, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. (Bethesda), 85: 271-291, 1993.
16. Gerrits, C. J. H., Creemers, G. J., Schellens, J. H. M., Wissel, P., Planting, A. S., Kunka, R., Selinger, K., de Boer-Dennert, M., Marijnen, Y., Harteveld, M., and Verweij, J. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily X 5 intravenous administration. Br. J. Cancer, 73: 744-750, 1996.
17. Rothenberg, M. L., Kuhn, J. G., Burris, H. A., III, Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., Rodriguez, G. I., Rock, M. K., Terada, K., and Von Hoff, D. D. A Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol., 11: 2194-2204, 1993.
18. Grochow, L. B., Rowinsky, E. K., Johnson, R., Ludeman, S., Kaufmann, S. H., McCabe, F. L., Smith, B. R., Hurowitz, L., DeLisa, A., Donehower, R. C., and Noe, D. A. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos., 20: 706-713, 1992.